Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lattice SSFRT followed by iparomlimab + tuvonralimab + bevacizumab in massive hepatocellular carcinoma
ChiCTR2500114229Phase 4Not yet recruiting
- Sponsor
- Southwest Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of iparomlimab, tuvonralimab and bevacizumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Southwest Medical University. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500114229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114229.